← Back to Clinical Trials
Recruiting NCT06659835

NCT06659835 Amino Acid Loss During Continuous Renal Replacement Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06659835
Status Recruiting
Phase
Sponsor Medical University of Vienna
Condition Renal Insufficiency
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-02-08
Primary Completion 2026-09

Trial Parameters

Condition Renal Insufficiency
Sponsor Medical University of Vienna
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-02-08
Completion 2026-09

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational study is to learn about amino acid loss during continuous renal replacement therapy and plasma amino acid levels in intensive care patients. The main questions it aims to answer are: What amount of amino acids is lost over the duration of continuous renal replacement therapy? How do amino acid plasma concentrations change over time in patients with and without continuous renal replacement therapy? Amino acid concentrations will be measured in the effluent and in the plasma of patients receiving continuous renal replacement therapy as part of their regular medical care. In addition, plasma concentrations of amino acids will be studied in patients without renal replacement therapy.

Eligibility Criteria

Inclusion criteria: * Postoperative ICU patients * Age ≥ 18 years * Patients on enteral or/and parenteral nutrition given according to internal standard operating procedure A) CRRT group: \- CRRT treatment planned; all types of CRRT (continuous veno-venous hemodialysis (CVVHD), continuous veno-venous hemodiafiltration (CVVHDF), continuous veno-venous hemofiltration (CVVH)) B)Non-CRRT group: * no current or previous (\<30 days) continuous or intermittent RRT * no chronic kidney disease stage G3-G5 Exclusion criteria: * Preoperative intensive care patients * Patients with liver cirrhosis stage 1-3 according to the Child-Pugh classification * Patients with acute liver failure

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology